The France Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The France Journal.

Press releases published on May 14, 2026

Cognisee Names Dr. Olaf Witkowski Chief Scientist as Frontier AI Moves Beyond LLMs
‘Key of Bones’ Reveals New Poster and Cannes Fantastic Pavilion Gala Screening
Spotlight on the Opening of the China Pavilion at Cannes: China Film Night Celebrates the Power of Eastern Storytelling
MontaVista Software and KMC Controls Collaborate to Deliver Carrier-Grade Intelligent Building Automation Platform
Customs Declarations UK Goes Live with French ELO Delivering End-to-End Channel Crossing Compliance in a Single Platform
Titan OS expands FAST lineup with the launch of Tennis Channel across Titan OS-powered TVs
KKday et JR East renforcent leur partenariat pour développer le tourisme ferroviaire dans l’est du Japon
Casella Waste Systems and Waga Energy Unveil RNG Facility at Ribbon Cutting
Academy Award Nominee Eric Roberts  Joins Cast of Chiaramonte Films, Inc.’s  Latest Feature, 'Ricardo Del Rey'
Rarecells Recognized Among Top 5 Disruptive Health Technologies with the Potential to Change the World by Maynooth University’s Innovation Value Institute
XS.com poursuit sa série d’événements en Amérique latine avec un parrainage Diamond au Rankia Mexique
21shares Launches TKNS, Its First Actively Managed Crypto ETF, Bringing Dynamic Digital Asset Exposure to U.S. Investors
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
Ipsen présente la corabotase, un neuro-inhibiteur recombinant (RNI™) « premier de sa classe », lors du symposium SCALE

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The France Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.